In particular, high tumor infiltrating lymphocytes (TILs) correlated with higher rates of pathological complete response in the neoadjuvant treatment setting [11,12,13], as well as with better OS in aBC patients receiving dual anti-HER2 blockade [14]. This evidence concerns the gene ERBB2 and neoplasm.